SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs rally is drawing support from Morgan Stanleys bullish view, the proposed Florida methane pipeline to supply Starship launches, and anticipation around Flight 15. Bulls point to momentum and growth potential, while skeptics cite the companys high valuation, losses, and pending share unlocks.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias breakout to fresh highs amid a broader AI-led tech rally is driving attention, with many traders cheering the momentum and looking for further gains. Others warn of a failed breakout or profit-taking and question whether high valuations, rising yields, and AI spending risks could weigh on the stock.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavaxs sharp rally is being linked by traders to reports of a suspected plague exposure in Russia, with speculation that renewed pandemic-preparedness interest and the stocks high short interest could amplify the move. Others cite updated Nuvaxovid approvals and Sanofi/Takeda partnerships, while skeptics say the outbreak connection and short-squeeze thesis remain uncertain.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Michael Caputos appointment to the Presidents Cancer Panel and his public engagement with ImmunityBio chair Patrick Soon-Shiong have fueled speculation that Anktiva could gain broader access, though no policy change has been confirmed. Traders are also debating the stocks sharp breakout and potential short squeeze, while some caution that the rally has lacked a new company announcement and that an FDA label expansion remains pending.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

A sharp momentum rally and breakout toward the $15 level, accompanied by elevated volume, has drawn attention to DNA. Bulls see renewed interest in Ginkgos AI-driven autonomous-lab strategy and partnerships, while skeptics argue the company still needs to prove commercial traction and revenue growth.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is drawing attention amid continued share-price weakness, with traders debating short pressure and broader rate concerns against company-specific risks. Skeptics focus on financing and potential dilution, limited disclosure, and whether major AI-data-center projects will be completed and generate revenue; bulls point to reported deployments and contract potential.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMCs move to new highs is drawing attention amid Elon Musks confirmation of preliminary talks about possible TSMC involvement in Terafab, his Texas chip venture. Traders view a potential partnership as a boost, though some stress no deal is finalized and debate whether TSMC would supplement or replace Intel; broader optimism about AI-chip demand and breakout momentum also features prominently.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Brazils presidential first-round results, with Flvio Bolsonaro outperforming expectations and forcing a runoff against Lula, are driving EWZs sharp rally and exceptional trading activity. Traders are broadly upbeat on the prospect of a business-friendly shift, reflected in call buying, while the runoff and political uncertainty remain sources of risk.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reports that Lundbeck is exploring an acquisition of Xeris have driven takeover and bidding-war speculation alongside heavy trading, though Xeris has said it is not for sale. Traders debate whether the chatter signals a potential deal or whether the stocks prospects rest more on Recorlev growth and XP-8121s development; no transaction is confirmed.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas announced addition to the Nasdaq-100 is driving expectations of index-fund buying and a possible short squeeze, following a rally tied to its Merck-partnered cancer-vaccine trial results. Traders are split between seeing further support from the inclusion and arguing the stock is overvalued after its sharp run-up.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Risk &amp; Discipline 
Full size on pivots only. On dips and rejections, 1/4 or 1/3 size — but really up to you. 
— Dan Shapiro 
 
$NVDA $TSLA $NVAX $CAPR

Cybin

StockTwits Web

Novavaxs sharp rally is being linked by traders to speculation around a reported Russian plague-lab outbreak, alongside the Sanofi/Takeda rollout of its updated COVID vaccine. The community is split over whether the move reflects vaccine-commercialization optimism or outbreak-driven FOMO, with heavy short interest adding to short-squeeze speculation; a direct connection between the outbreak and Novavax business remains uncertain.

Capricor Therapeutics Inc

Risk & Discipline 
Full size on pivots only. On dips and rejections, 1/4 or 1/3 size — but really up to you. 
— Dan Shapiro 
 
